Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast

ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results


ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2021.

"With top-line data from our pivotal SORAYA trial on track for release in Q4, we have accelerated preparations for the BLA submission and commercial launch of mirvetuximab. In parallel, we continue to generate data that support mirvetuximab as the combination agent of choice for ovarian cancer patients," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "At ASCO, we presented final data from our mirvetuximab plus Avastin® doublet, showing compelling and durable anti-tumor activity, with a 64% ORR, 11.8 month mDOR, and 10.6 month mPFS in patients with high FR? recurrent ovarian cancer, regardless of platinum status. We believe these data are highly encouraging, particularly given outcomes with available therapies in this setting. As we continue to accrue our confirmatory MIRASOL trial, we are working to establish mirvetuximab as the new standard of care in patients with high FR? ovarian cancer, who comprise roughly 40% of the market. To this end, this quarter we are initiating PICCOLO, a single-arm study of mirvetuximab monotherapy in recurrent platinum-sensitive ovarian cancer to support label expansion."

Enyedy added, "Beyond mirvetuximab, our IMGN632, IMGC936, and IMGN151 programs are progressing as anticipated. Patient accrual continues in our IMGN632 trials in BPDCN and AML, with data from our AML cohort expected at ASH next quarter. Our dose-escalation study of IMGC936 is enrolling in multiple solid tumor types and we are on track to file the IND for IMGN151 by year-end. With a focus on execution towards key inflection points, we look forward to transforming ImmunoGen into a fully integrated oncology company with the potential for two innovative ADCs on the market in 2022."

RECENT PROGRESS

ANTICIPATED UPCOMING EVENTS

FINANCIAL RESULTS

Revenues for the quarter ended June 30, 2021 were $16.9 million, compared with $15.0 million for the quarter ended June 30, 2020, which consisted primarily of non-cash royalty revenues.

Operating expenses for the second quarter of 2021 were $44.3 million, compared with $33.4 million for the same quarter in 2020. The increase was largely driven by research and development expenses, which were $34.6 million for the second quarter of 2021, compared with $22.9 million for the second quarter of 2020. This increase was due to greater clinical trial expenses driven by costs related to the MIRASOL, SORAYA, and IMGC936 studies, greater personnel and temporary staffing costs, and higher external manufacturing costs and third-party service fees in support of commercial readiness. General and administrative expenses for the second quarter of 2021 were $9.7 million, compared to $9.8 million for the second quarter of 2020.

Net loss for the second quarter of 2021 was $30.7 million, or $0.15 per basic and diluted share, compared to a net loss of $24.3 million, or $0.14 per basic and diluted share, for the second quarter of 2020. Weighted average shares outstanding increased to 199.9 million for the 2021 period from 174.4 million in the prior year.

ImmunoGen had $239.5 million in cash and cash equivalents as of June 30, 2021, compared with $293.9 million as of December 31, 2020, and had $1.1 million of convertible debt outstanding as of June 30, 2021, compared with $2.1 million as of December 31, 2020. Cash used in operations was $88.5 million for the first six months of 2021, compared with cash used in operations of $56.5 million for the same period in 2020. Capital expenditures were $(0.9) million for the first six months of 2021, compared with net proceeds from the sale of equipment of $1.4 million for the first six months of 2020.

FINANCIAL GUIDANCE

ImmunoGen's financial guidance for 2021 remains unchanged:

ImmunoGen expects that its current cash will fund operations into the second half of 2022.

CONFERENCE CALL INFORMATION

ImmunoGen will hold a conference call today at 8:00 a.m. ET to discuss these results. To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOWtm.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Avastin®, Vidaza®, and Venclexta® are registered trademarks of their respective owners.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the Company's revenues and operating expenses for the twelve months ending December 31, 2021; its cash and cash equivalents as of December 31, 2021; how long its current cash will fund operations, the occurrence, timing, and outcome of potential preclinical, clinical, and regulatory events related to the Company's product candidates; and the presentation of preclinical and clinical data on the Company's product candidates. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company's preclinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes; the Company's ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen's industry and business; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, and other reports filed with the Securities and Exchange Commission.

IMMUNOGEN, INC.
SELECTED FINANCIAL INFORMATION
(in thousands, except per share amounts)
 
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
 
June 30, December 31,

2021

2020

ASSETS
 
Cash and cash equivalents $

239,538

$

293,856

Other assets

61,908

61,216

 
Total assets $

301,446

$

355,072

 
LIABILITIES AND SHAREHOLDERS' EQUITY
 
Current portion of deferred revenue $

53,792

$

29,249

Other current liabilities

66,527

93,074

Long-term portion of deferred revenue

55,480

80,860

Other long-term liabilities

57,182

62,319

Shareholders' equity

68,465

89,570

 
Total liabilities and shareholders' equity $

301,446

$

355,072

 
 
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended Six Months Ended
June 30, June 30,

2021

 

 

2020

 

 

2021

 

 

2020

 
Revenues:
Non-cash royalty revenue $

16,690

$

14,075

$

32,235

$

27,072

License and milestone fees

252

945

409

1,228

Research and development support

6

5

10

12

 
Total revenues

16,948

15,025

32,654

28,312

 
Expenses:
Research and development

34,589

22,921

69,002

50,329

General and administrative

9,728

9,767

19,937

18,631

Restructuring charge

-

699

-

1,524

 
Total operating expenses

44,317

33,387

88,939

70,484

 
Loss from operations

(27,369)

(18,362)

(56,285)

(42,172)

 
Non-cash interest expense on liability related to sale of future royalty & convertible bonds

(3,557)

(6,081)

(8,201)

(11,783)

Interest expense on convertible bonds

(23)

(23)

(47)

(47)

Other income (loss), net

208

168

(259)

616

 
Net loss $

(30,741)

$

(24,298)

$

(64,792)

$

(53,386)

 
Basic and diluted net loss per common share $

(0.15)

$

(0.14)

$

(0.32)

$

(0.31)

 
Basic and diluted weighted average common shares outstanding

199,890

174,354

199,365

171,055

 


These press releases may also interest you

at 04:35
The global healthcare analytics market size is expected to reach USD 129.7 billion by 2028 and is expected to expand at a CAGR of 23.8% over the forecast period, according to a new report by Grand View Research, Inc., The rising need to enhance...

at 04:21
CGBIO Inc., a Korea's Regenerative Medicine company, announced on September 8, 2021 a...

at 04:00
OPEN Health has today announced the acquisition of London-based agency ARK. ARK has a unique approach to delivering data-driven, digital-first creative campaigns. Integrating the ARK business with the OPEN Health Group further strengthens our global...

at 04:00
Taiwania Capital, the first venture capital investment firm funded by the Taiwanese government, has demonstrated its investing prowess through the successful public listings of five portfolio companies in the U.S. and Taiwan: EirGenix, Inc. (with a...

at 04:00
The chronic condition IBD is marked by recurring phases of inflammation and remission of the gastrointestinal tract. With adequate treatment, the symptoms of the disease can be effectively managed for many patients to help improve their quality of...

at 03:30
Mind Cure Health Inc. (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licensing agreement with ATMA Journey Centers Inc. ("ATMA"), a pioneer in...



News published on 30 july 2021 at 06:35 and distributed by: